PHARMACOGENOMICS药物基因组学
PHARMACOGENOMICS(英文缩写 PHARMACOGENOMICS),ISSN 1462-2416,eISSN 1744-8042,中文译名:药物基因组学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.638 | Q3 |
| 2022 | 2.100 | Q4 |
| 2023 | 1.900 | Q3 |
| 2024 | 1.900 | Q3 |
| 2025 | 1.600 | Q4 |
PHARMACOGENOMICS 最新收录文献
-
1. The influence of pharmacogenetics on the treatment-related outcomes of antidepressants and antipsychotics in Brazil: a systematic review.
PMID:日期:2026-09-15Pharmacogenetics investigates how genetic variability influences drug response, with particular relevance in psychiatry, where treatment often requires trial-and-error approaches. However, most pharmacogenetic evidence derives from predominantly European populations, limiting its applicability to admixed populations like Brazil's. This study aimed to synthesize evidence on genetic determinants of antidepressant and antipsychotic treatment outcomes in Brazilian populations. PubMed, Embase, BVS/Bireme and Google Scholar were systematically searched up to January 2026. Two reviewers screened studies and assessed quality. Eligible studies were observational, conducted in Brazil, evaluating pharmacogenetic influences on adults using antidepressants or antipsychotics. 19 papers were included, comprising 2,590 participants; 46% females. In schizophrenia, variants in , , , and were associated with clozapine safety and response. In bipolar disorder, variants were linked to lower Glu/GABA ratio. In major depressive disorder, all ultrarapid metabolizers required combination therapy to achieve remission. For smoking cessation, rs2279343 AA showed greater success with bupropion. In obsessive-compulsive disorder, and variants were associated with differential treatment response. Brazilian studies report relevant gene-drug associations, but sample limitations reduce generalizability. Therefore, routine pharmacogenetic testing in Brazilian psychiatric practice remains premature. PROSPERO CRD42024533782.
-
2. Pharmacogenomics and artificial intelligence in cardiovascular disease: emerging tools for precision medicine.
PMID:日期:2026-09-14Cardiovascular diseases (CVD) remain a predominant cause of mortality and morbidity globally. Conventional therapy methods may be constrained by their inadequate acknowledgment of individual genetic and clinical variations. In this context, pharmacogenetics and artificial intelligence (AI) applications, essential elements of the precision medicine approach, present a novel paradigm for the management of cardiovascular disorders. Pharmacogenetics elucidates the genetic basis of individual responses to drugs, thereby improving treatment success and minimizing adverse drug effects. Conversely, artificial intelligence facilitates enhanced diagnostic accuracy, risk assessment, and treatment strategy formulation through the analysis of extensive and complex clinical, genetic, and imaging datasets. The amalgamation of these two domains provides substantial benefits in formulating tailored treatment plans and enhances clinical decision-making processes. Nonetheless, obstacles including data security, ethical concerns, and insufficient clinical validation hinder the extensive adoption of these technologies. In conclusion, the integration of pharmacogenetics and artificial intelligence has considerable promise for the enhanced, secure, and individualized management of cardiovascular illnesses. PubMed, Google Scholar, Scopus, and Web of Science were searched for relevant literature published from 1990 to 2026, with particular emphasis on recent and clinically relevant studies.
-
3. {"_":"Role of polymorphism in tramadol analgesia following third molar surgery: a pharmacogenomic study.","i":["OPRM1 A118G"]}
PMID:日期:2026-09-11The polymorphism has been implicated in interindividual variability in opioid analgesic response, but its influence on tramadol efficacy remains uncertain. This study evaluated the association between and postoperative analgesic response to tramadol following mandibular third molar surgery. In this prospective pharmacogenomic study, 53 adults undergoing impacted mandibular third molar extraction were enrolled. Genomic DNA was analyzed for using amplification refractory mutation system polymerase chain reaction (ARMS-PCR). All procedures were performed under 2% lignocaine with adrenaline. Tramadol (50 mg) was administered after the onset of postoperative pain. Pain intensity was assessed using the Visual Analogue Scale (VAS) and Short-Form McGill Pain Questionnaire at 2, 4, and 6 hours. The primary outcome was summed pain intensity difference (SPID, 2-6 hours). Genotype frequencies were in Hardy-Weinberg equilibrium. No significant association was observed between genotype and SPID, VAS reduction, Pain Rating Index change, or responder status during the 6-hour observation period (all > 0.05). was not significantly associated with early tramadol analgesic response following third molar surgery.
-
4. Genetic variation and response to platinum chemotherapy in cancer treatment: a review article.
PMID:日期:2026-09-11Platinum-based chemotherapies, including cisplatin, carboplatin, and oxaliplatin, are foundational treatments of multiple solid tumor types, inducing cell death via DNA cross-linking. Genetic markers of DNA repair have been extensively studied as determinants of response. We searched MEDLINE (2000-2026) and appraised 204 publications, contributing 212 study entries, against a four-tier evidence hierarchy, distinguishing throughout between prognostic vs. predictive biomarker claims. Defects in nucleotide excision repair and homologous recombination repair are associated with outcomes with platinum therapy across nearly every tumor type examined. Evidence supporting these markers as predictors of platinum-specific benefit is far narrower. Of 212 entries reviewed, only 10 compared platinum against an alternative regimen under randomized allocation, and five of these found no differential benefit. Homologous recombination deficiency predicts benefit from platinum-based therapy in high-grade serous ovarian carcinoma and randomized data support a predictive role for germline mutations in triple-negative breast cancer. For ERCC1, two randomized trials disagree, and no assay identified in this review distinguishes the single isoform competent to form the incision complex with XPF.
-
5. Mapping the development pipeline of genomic point-of-care tests: a horizon scan.
PMID:日期:2026-09-10As precision medicine increasingly relies on genetic information, the development of reliable genomic point-of-care tests (POCTs) is essential. However, the number of technologies that have reached true clinical usability is limited. There is a growing need for POCTs that enable rapid, accurate analysis of human genetic variation, particularly across diverse clinical settings without requiring specialist expertise. This horizon scan aimed to provide an overview of the development pipeline of POCTs to identify variation(s) in the genome and epigenome that enable the use of genetic information to inform diagnosis, prognosis, and treatment decisions in any clinical area. Database (Embase and MEDLINE) and clinical trial registry (ClinicalTrials.gov) searches were conducted from 2019 to 19 December 2024; 346 unique technologies were identified. A range of purposes and conditions were identified; the most common being diagnosis ( = 263) and cancer ( = 237) respectively. We defined 'true POCTs' as those that were highly automated, capable of analyzing complex samples, and operable by non-specialists. Only 36 met these criteria; six are already on the market, one is in clinical trials, and the remaining 29 are at various stages of development. Overall, most technologies were in early stages of development, highlighting the need for further innovation and validation.
-
6. Development and psychometric validation of the pharmacogenetic Knowledge, attitudes, and Awareness scale (P-KAAS): an initial validation study in undergraduate nursing students.
6. 药物基因组学知识、态度与意识量表（P-KAAS）的开发及心理测量学验证：一项在本科护理学生中的初步验证研究PMID:日期:2026-09-10Pharmacogenetics is a key component of precision medicine, yet its integration into clinical practice remains limited. This study aimed to develop and validate the Pharmacogenetic Knowledge, Attitudes and Awareness Scale (P-KAAS) and assess nursing students' pharmacogenetic competencies. This methodological, cross-sectional scale-development study included 312 undergraduate nursing students. Content validity was evaluated by an expert panel using the Davis technique. Construct validity was assessed using exploratory factor analysis (EFA) and known-groups validity analyses. Internal consistency, item-total correlations, and test-retest reliability were examined. Students demonstrated moderate awareness and positive attitudes toward pharmacogenetics but limited detailed knowledge. EFA identified a two-factor structure explaining 60.99% of the total variance, with factor loadings ranging from 0.438 to 0.725. Known-groups validity analyses demonstrated significant differences in P-KAAS scores according to academic year and prior exposure to pharmacogenetics. Cronbach's alpha was 0.929 for the total scale, 0.696 for the Knowledge subscale, and 0.938 for the Attitude and Awareness subscale. Test-retest correlations ranged from 0.87 to 0.90. The P-KAAS demonstrated satisfactory psychometric properties among undergraduate nursing students. Further validation in other healthcare professional groups is warranted before broader application.
-
7. Co-designing a study on perspectives toward pharmacogenomic testing in mental health care among youth and caregivers.
PMID:日期:2026-08-17Finding suitable psychotropic medications can be a lengthy trial-and-error process, leading to poor symptom control, low adherence, and treatment failure. Pharmacogenomic (PGx) testing can help inform prescribing considerations for some individuals. As PGx becomes more common in Canada, understanding patients' and families' hopes, expectations, and concerns is vital. This article details our work engaging two advisory councils comprised of five youth with lived/living experience of mental health challenges and five caregivers across four videoconferencing sessions (between June 2025 and February 2026) aimed at co-designing a qualitative study on perceptions of PGx testing for psychotropic medication prescribing among youth and caregivers. Verbal and written input was gathered from council members and incorporated using iterative feedback cycles. The advisory councils challenged our assumptions and ensured the study design aligned with their lived-experience perspectives. Some suggestions differed between youth and caregiver advisors. Impacts included changes to eligibility criteria, flexible participation options to promote accessibility, and the use of inclusive language in study materials. We recommend that future PGx research actively involves those with lived/living experience to ensure the field is shaped by those it aims to serve.
-
8. The pharmacogenetic of cyclosporine in Tunisian renal transplantation.
PMID:日期:2026-08-15Our study is the first study, in Tunisia, to investigate the effect of SNPs in , , , and genes on the response to cyclosporine (CsA). In a retrospective study, a total of 78 renal transplant patients receiving CsA and mycophenolate mofetil (MMF) were recruited. Genotyping was performed using PROFLEX-PCR followed by RFLP. We found a significant lower C0/D CsA in patients with at least one allele compared to the wild type ( = 0.001). We found a statistically significant increased risk of acute and chronic rejection associated with carrying or compared to the and of carrying or compared to the ( = 0.001). The occurrence of leukopenia was significantly decreased in patients with at least one allele ( = 0.01). and the occurrence of diarrhea was significantly increased in patients carrying the variant allele of ( = 0.005). Our results support the usefulness of CsA pharmacokinetics tests in prekidney transplant assessments.
-
9. Current knowledge in pharmacogenomics and precision medicine: perspectives of the PGRN global PGx committee on improving drug therapies in underrepresented ethnic populations.
PMID:日期:2026-07-01A precision medicine strategy is likely to be more impactful, when pharmacogenomics (PGx) guided selection of drugs and dosage wherever applicable is implemented across the globe. In regions where resources are disproportionately distributed, PGx implementation in routine clinical care can play a critical role in ensuring the optimal use of limited healthcare infrastructure. At present, PGx data from the majority of the distinct ethnic populations across Asia, Africa, and South America is limited. While international consortia, working groups, and scientific bodies have made significant contributions toward evaluating the evidence for PGx implementation, the majority of existing guidelines and recommendations are derived primarily from studies conducted in a limited number of ethnic groups. Precision Medicine Initiatives in countries like Korea, Taiwan, and Malaysia and PGx organizations like the African Institute of Biomedical Science and Technology (AiBST), Consortium for Genomics & Therapeutics in Africa (CGTA), implementation of pharmacogenetic testing for the effective care and treatment in Africa, Greater Middle East (GME) whole exome sequencing program, Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF), Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM), Latin American Network for Validation and Implementation of Pharmacogenomic Clinical Guidelines (RELIVAF), IndiGen initiative, Southeast Asian Pharmacogenomics Research Network (SEAPharm), are working toward consolidating the PGx presence in these regions.
-
10. U.S. student pharmacists perspectives on the pharmacogenomics of escitalopram and aripiprazole.
PMID:日期:2026-07-01Major depressive disorder (MDD) remains a significant illness worldwide, yet antidepressant therapy often follows an empirical "trial-and-error" approach. Escitalopram, a selective serotonin reuptake inhibitor is approved for MDD and generalized anxiety disorders, while aripiprazole (ARI), an atypical antipsychotic, is used as adjunctive therapy in treatment-resistant depression. Despite the broad availability of these agents, outcomes remain suboptimal. Data from the STAR*D trial indicate that only one-third of patients achieve remission after their first antidepressant trial, with many requiring multiple adjustments. This reactive approach prolongs symptom burden, increases adverse effects, and delays effective treatment.Advances in pharmacogenomics now offer a means to individualize therapy by identifying genetic polymorphisms - such as those found in CYP2C19 and CYP2D6-that influence escitalopram and aripiprazole metabolism and response. This literature review examines the evidence linking pharmacogenomic variability to antidepressant outcomes and explores how implementing genetic-guided prescribing can improve efficacy, reduce adverse effects, and enhance the pharmacists' role in mental health care.